Siglec-G–CD24 axis controls the severity of graft-versus-host disease in mice

Increase in severity of graft versus host disease by cytomegalovirus.

An allogeneic transplant recipient developed severe graft versus host disease (GvHD) 48 days after transplantation that was concomitant with a cytomegalovirus (CMV) viraemia, from which she subsequently died. CMV infection was detected in blood by the polymerase chain reaction and later in tissue by immunohistochemical techniques. CMV should be considered in patients in whom GvHD does not respo...

In vivo imaging of graft-versus-host-disease in mice.

We have developed a mouse system by which to track the migration and homing of cells in a setting of bone marrow transplantation (BMT)-induced graft-versus-host disease (GVHD) after systemic infusion using enhanced green fluorescence protein (eGFP) transgenic (Tg) cells and a simple application of a fluorescence stereomicroscope outfitted with a color charge-coupled device (CCD) camera. Whole b...

Graft Versus Host Disease

Commonly referred to as GVHD, graft-versus-host disease is a man-made condition that arises when patients are transplanted with donor tissue that is not identical to their own. Transplants from other individuals are called allogeneic (‘allo’ meaning ‘other’ and ‘geneic’ referring to ‘genes’). GVHD occurs after hematopoietic stem cell or bone marrow transplantation but is most commonly experienc...

Graft versus Host Disease

Definition Graft-versus-host disease (GVHD) is the most common complication of allogeneic hematopoietic stem cell transplantation (HSCT). In HSCT, the patient’s bone marrow is destroyed with chemotherapy and/or radiation and replaced by donor hematopoietic stem cells. In allogeneic HSCT the donor is usually a close family member or occasionally someone outside the family who has been found to b...

Graft-versus-host disease or graft-versus-host-like syndrome.